1
|
Umeki Y, Matsuoka H, Fujita M, Goto A, Serizawa A, Nakamura K, Akimoto S, Nakauchi M, Tanaka T, Shibasaki S, Inaba K, Uyama I, Suda K. Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study. Intern Med 2023; 62:319-325. [PMID: 36725064 PMCID: PMC9970804 DOI: 10.2169/internalmedicine.9751-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Objective The aim of this study was to determine the safety and clinical efficacy of docetaxel+cisplatin+5-fluorouracil (DCF) as neoadjuvant chemotherapy (NAC). Methods In this single-center study, patient background and treatment outcomes (NAC efficacy assessment, NAC adverse events, short-term postoperative outcomes, and one-year postoperative outcomes) in patients treated with preoperative DCF and preoperative cisplatin+5-FU (CF) were compared retrospectively. Patients Seventeen patients diagnosed with esophageal squamous cell carcinoma (ESCC) and treated with preoperative DCF therapy and 50 patients treated with preoperative CF therapy between January 2013 and July 2019 were included in this study. Results There were significant differences in clinical T factor and clinical stage between the CF and DCF groups (p<0.05). All patients in the DCF therapy group were above clinical T3 and clinical stage III. The clinical response after NAC was partial response (PR) for 23 patients (46.0%) in the CF group and 13 patients (76.5%) in the DCF group (p=0.030). Regarding adverse events in NAC, neutropenia, febrile neutropenia (FN), diarrhea, and stomatitis were observed more frequently in the DCF group than in the CF group (p<0.05). The postoperative results [overall survival (OS), recurrence-free survival (RFS), one-year OS, one-year RFS] of the DCF group were comparable to those of the CF group. Conclusion DCF therapy has been recognized as an effective treatment option for advanced ESCC. However, the indication for DCF therapy should be chosen carefully because of the high incidence of adverse events.
Collapse
Affiliation(s)
- Yusuke Umeki
- Department of Surgery, Fujita Health University, Japan
| | | | | | - Ai Goto
- Department of Surgery, Fujita Health University, Japan
| | | | | | | | - Masaya Nakauchi
- Department of Advanced Robotic and Endoscopic Surgery, Fujita Health University, Japan
| | - Tsuyoshi Tanaka
- Collaborative Laboratory for Research and Development in Advanced Surgical Technology, Fujita Health University, Japan
| | | | - Kazuki Inaba
- Department of Advanced Robotic and Endoscopic Surgery, Fujita Health University, Japan
| | - Ichiro Uyama
- Department of Advanced Robotic and Endoscopic Surgery, Fujita Health University, Japan
- Collaborative Laboratory for Research and Development in Advanced Surgical Technology, Fujita Health University, Japan
| | - Koichi Suda
- Department of Surgery, Fujita Health University, Japan
- Collaborative Laboratory for Research and Development in Advanced Surgical Intelligence, Fujita Health University, Japan
| |
Collapse
|
2
|
Moradi F, Farolfi A, Fanti S, Iagaru A. Prostate cancer: Molecular imaging and MRI. Eur J Radiol 2021; 143:109893. [PMID: 34391061 DOI: 10.1016/j.ejrad.2021.109893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 07/26/2021] [Accepted: 08/01/2021] [Indexed: 10/20/2022]
Abstract
The role of molecular imaging in initial evaluation of men with presumed or established diagnosis of prostate cancer and work up of biochemical recurrence and metastatic disease is rapidly evolving due to superior diagnostic performance compared to anatomic imaging. However, variable tumor biology and expression of transmembrane proteins or metabolic alterations poses a challenge. We review the evidence and controversies with emphasis on emerging PET radiopharmaceuticals and experience on clinical utility of PET/CT and PET/MRI in diagnosis and management of prostate cancer.
Collapse
Affiliation(s)
- Farshad Moradi
- Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford University, Stanford, CA, USA.
| | - Andrea Farolfi
- Nuclear Medicine Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Stefano Fanti
- Nuclear Medicine Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Andrei Iagaru
- Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford University, Stanford, CA, USA
| |
Collapse
|
3
|
Wagle MC, Castillo J, Srinivasan S, Holcomb T, Yuen KC, Kadel EE, Mariathasan S, Halligan DL, Carr AR, Bylesjo M, McAdam PR, Lynagh S, Marien KM, Kockx M, Waumans Y, Huang SMA, Lackner MR, Mounir Z. Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. Cancer Immunol Res 2020; 8:844-850. [PMID: 32321776 DOI: 10.1158/2326-6066.cir-19-0568] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Revised: 11/01/2019] [Accepted: 04/17/2020] [Indexed: 11/16/2022]
Abstract
Prostate cancer is the second leading cause of cancer-related death in men. Despite having a relatively lower tumor mutational burden than most tumor types, multiple gene fusions such as TMPRSS2:ERG have been characterized and linked to more aggressive disease. Individual tumor samples have been found to contain multiple fusions, and it remains unknown whether these fusions increase tumor immunogenicity. Here, we investigated the role of fusion burden on the prevalence and expression of key molecular and immune effectors in prostate cancer tissue specimens that represented the different stages of disease progression and androgen sensitivity, including hormone-sensitive and castration-resistant prostate cancer. We found that tumor fusion burden was inversely correlated with tumor mutational burden and not associated with disease stage. High fusion burden correlated with high immune infiltration, PD-L1 expression on immune cells, and immune signatures, representing activation of T cells and M1 macrophages. High fusion burden inversely correlated with immune-suppressive signatures. Our findings suggest that high tumor fusion burden may be a more appropriate biomarker than tumor mutational burden in prostate cancer, as it more closely associates with immunogenicity, and suggests that tumors with high fusion burden could be potential candidates for immunotherapeutic agents.
Collapse
Affiliation(s)
- Marie-Claire Wagle
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
| | - Joseph Castillo
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California
| | | | - Thomas Holcomb
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California
| | - Kobe C Yuen
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California
| | - Edward E Kadel
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California
| | - Sanjeev Mariathasan
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California
| | | | - Adrian R Carr
- Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom
| | - Max Bylesjo
- Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom
| | - Paul R McAdam
- Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom
| | - Sarah Lynagh
- Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom
| | | | | | | | - Shih-Min A Huang
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California
| | - Mark R Lackner
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California
| | - Zineb Mounir
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
| |
Collapse
|
4
|
Herden J, Wittekind C, Weissbach L. Discrepancy between theory and practice of the clinical tumor-nodes-metastasis (TNM) classification for localized prostate cancer. ANNALS OF TRANSLATIONAL MEDICINE 2019; 7:250. [PMID: 31317020 DOI: 10.21037/atm.2019.05.42] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Jan Herden
- Department of Urology, University Hospital Cologne, Cologne, Germany
| | | | | |
Collapse
|
5
|
Bandini M, Preisser F. UICC and AJCC 8th edition tumor-nodes-metastasis (TNM) classifications for patients treated with radical prostatectomy: reliable but not infallible prognostic tools. ANNALS OF TRANSLATIONAL MEDICINE 2019; 7:S41. [PMID: 31032320 PMCID: PMC6462615 DOI: 10.21037/atm.2019.02.26] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Accepted: 02/21/2019] [Indexed: 11/06/2022]
Affiliation(s)
- Marco Bandini
- Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy
| | - Felix Preisser
- Department of Urology, University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|